Johnson & Johnson (UKEX:JNJ)
â‚´ 5947 0 (0%) Market Cap: 14.82 Til Enterprise Value: 15.47 Til PE Ratio: 24.01 PB Ratio: 4.98 GF Score: 84/100

Johnson & Johnson at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 28, 2021 / 02:00PM GMT
Louise Alesandra Chen;Scott White
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD;Johnson &

Good morning. I'm Louise Chen, the large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Johnson & Johnson. Johnson & Johnson is a leading global health care company with a diversified business model that includes Pharmaceuticals, Medical Devices and Consumer. The company's Pharmaceutical business has been a top performer in the industry. 2021 could be in Johnson & Johnson's 10th consecutive year of above-market growth. Therefore, we are thrilled to have with us today, Mathai Mammen, Global Head of R&D for the Janssen Pharmaceutical Companies of Johnson & Johnson; and Scott White, company group Chairman of North America Pharmaceuticals, to discuss the potential of Johnson & Johnson's commercial products and pipeline of its first-in-class and best-in-class drugs.

So before we start the Q&A, Mathai and Scott, would you like to make any opening remarks?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot